New technology aids in prostate cancer treatment

May 12, 2010

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

The improved Fluorescence In-Situ Hybridization (FISH) platform uses DNA probes to analyze the three-dimensional space cancer cells occupy in routine clinical microscopic analysis of tissue sections of tumors. It will provide a more accurate way of identifying PTEN loss in biopsies and tissue sections so doctors can better match the type and amount of treatment to the aggressiveness of a tumor.

"The idea is that this test could be used in new cases of to help decide which of the many options is best suited for more aggressive cancers " says Jeremy Squire, who worked with a team of researchers in the Department of Pathology and . "The patient treatment from the get-go will be more appropriately planned."

PTEN is found in the nucleus of and is considered one of the most important cancer-causing tumor-suppressor genes. If there is loss in the PTEN, it can inhibit the patient's ability to fight the cancer. It plays a critical role in a variety of cancers including prostate, breast, and lung cancers.

PARTEQ Innovations, the technology transfer office of Queen's University has licensed the technology to Cymogen Dx. The company expects to make the technology available to research and clinical markets in the near future.

Explore further: Chronic inflammation linked to 'high-grade' prostate cancer

add to favorites email to friend print save as pdf

Related Stories

Preventing prostate cancer the complex way

Feb 03, 2009

(PhysOrg.com) -- Blocking a specific protein complex prevents the formation of tumors in mice genetically predisposed to develop prostate cancer, researchers at the Whitehead Institute for Biomedical Research ...

Gene helps protect tumor suppressor in breast cancer

Apr 06, 2009

Scientists at The University of Texas M. D. Anderson Cancer Center have discovered a gene that protects PTEN, a major tumor-suppressor that is reduced but rarely mutated in about half of all breast cancers.

Recommended for you

Unraveling the 'black ribbon' around lung cancer

19 hours ago

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments : 0

More news stories

Leeches help save woman's ear after pit bull mauling

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

Male monkey filmed caring for dying mate (w/ Video)

(Phys.org) —The incident was captured by Dr Bruna Bezerra and colleagues in the Atlantic Forest in the Northeast of Brazil.  Dr Bezerra is a Research Associate at the University of Bristol and a Professor ...

Scientists tether lionfish to Cayman reefs

Research done by U.S. scientists in the Cayman Islands suggests that native predators can be trained to gobble up invasive lionfish that colonize regional reefs and voraciously prey on juvenile marine creatures.